Sandoz, a subsidiary division of Novartis, has launched its infliximab biosimilar, Zessly, in Germany. The launch brings the number of infliximab biosimilars available in Germany to 3.
Sandoz, a subsidiary division of Novartis, recently launched its infliximab biosimilar, Zessly, in Germany. The launch brings the number of infliximab biosimilars available in Germany to 3.
In May 2018, the European Commission authorized the biosimilar for sale in the European Union (EU). Germany will be the first European market where the drug will be available for all indications of the reference product: rheumatoid arthritis (RA), adult Crohn disease, pediatric Crohn disease, adult ulcerative colitis, pediatric ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.
The approval was based on a review of the data that demonstrated the infliximab biosimilar was equivalent to the reference product in terms of both safety and efficacy. The data included a phase 3 confirmatory study in RA that met its primary endpoint of achieving the American College of Rheumatology’s criteria for a 20% improvement (ACR20) response at week 14.
Reference infliximab, sold as Remicade and developed by Johnson & Johnson (J&J), earned an estimated $6.3 billion globally in 2017. However, increased competition from biosimilars is starting to eat away at its market share. During an investor call earlier this year that discussed fourth quarter sales from 2017, it was announced that Remicade sales fell by 9.7% worldwide.
In the United States, Remicade faces biosimilar competition from 2 products: Celltrion and Pfizer’s Inflectra, and Samsung Bioepis and Merck’s Renflexis. In the European Unoin, J&J’s reference infliximab fights for market share from the same products, though Renflexis is marketed under the brand name Flixabi, and Inflectra is marketed under 2 names: Inflectra and Remsima.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).
Biosimilars Business Roundup For August 2023—Podcast Edition
September 5th 2023On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.
AMCP Nexus: Panelists Share Current Scope of Biosimilar Industry
October 26th 2023Panelists at the Academy of Managed Care Pharmacy (AMCP) Nexus meeting chronicled the current state of the US biosimilar market, including current policies impacting the market, recent regulatory decisions, and the developing arguments around requirements for clinical efficacy studies.
Report: Conflicting Guidelines, Rebate Walls Are Major Factors Determining Biosimilar Uptake
October 24th 2023Samsung Bioepis’ most recent biosimilar market report identified inconsistent medical guidelines, challenges with access and rebates, and acute vs chronic treatment duration as major factors influencing biosimilar uptake in the United States.